UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

KRAS: From undruggable to a druggable Cancer Target

Cancer treatment reviews, 2020-09, Vol.89, p.102070-102070, Article 102070

2020

Volltextzugriff (PDF)

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

The oncologist (Dayton, Ohio), 2015-06, Vol.20 (6), p.660-673

2015

Volltextzugriff (PDF)

The clinical development of MEK inhibitors

Nature reviews. Clinical oncology, 2014-07, Vol.11 (7), p.385-400

2014

Volltextzugriff (PDF)

Lung Cancer Worldwide

Journal of thoracic oncology, 2019-06, Vol.14 (6), p.956-956

Adjei, Alex A.

2019

Volltextzugriff (PDF)

Current Diagnosis and Management of Small-Cell Lung Cancer

Mayo Clinic proceedings, 2019-08, Vol.94 (8), p.1599-1622

2019

Volltextzugriff (PDF)

MET: a promising anticancer therapeutic target

Nature reviews. Clinical oncology, 2012-06, Vol.9 (6), p.314-326

2012

Volltextzugriff (PDF)

The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024

Journal of thoracic oncology, 2023-10, Vol.18 (10), p.1257-1257

Adjei, Alex A.

2023

Volltextzugriff (PDF)

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Journal of thoracic oncology, 2020-08, Vol.15 (8), p.1281-1297

2020

Volltextzugriff (PDF)

A systematic review of the business case for corporate social responsibility and firm performance

Corporate social-responsibility and environmental management, 2020-03, Vol.27 (2), p.444-454

2020

Volltextzugriff (PDF)

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Cancer treatment reviews, 2014-09, Vol.40 (8), p.917-926

2014

Volltextzugriff (PDF)

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

CA: a cancer journal for clinicians, 2013-07, Vol.63 (4), p.249-279

2013

Volltextzugriff (PDF)

FGFR Signaling as a Target for Lung Cancer Therapy

Journal of thoracic oncology, 2016-01, Vol.11 (1), p.9-20

2016

Volltextzugriff (PDF)

Tackling the High Cost of Oncology Drugs

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1774-1777

Adjei, Alex A.

2021

Volltextzugriff (PDF)

All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC

Journal of thoracic oncology, 2021-09, Vol.16 (9), p.1429-1433

2021

Volltextzugriff (PDF)

Lung cancer and metastasis: new opportunities and challenges

Cancer and metastasis reviews, 2015-06, Vol.34 (2), p.169-171

2015

Volltextzugriff (PDF)

Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-01, Vol.163, p.96-106

2022

Volltextzugriff (PDF)

A Call to Arms: Reducing Disparities in Lung Cancer Care Worldwide

Journal of thoracic oncology, 2020-11, Vol.15 (11), p.1700-1702

Adjei, Alex A.

2020

Volltextzugriff (PDF)

Controversies in Thoracic Oncology

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.366-367

Adjei, Alex A.

2021

Volltextzugriff (PDF)

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

Clinical cancer research, 2008-01, Vol.14 (2), p.342-346

2008

Volltextzugriff (PDF)

Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

Journal of thoracic oncology, 2016-12, Vol.11 (12), p.2048-2050

2016

Volltextzugriff (PDF)

Expanding the KRASG12C Inhibitor Class: What Do We Need Next?

Journal of thoracic oncology, 2023-07, Vol.18 (7), p.844-846

2023

Volltextzugriff (PDF)

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer

Cancer treatment reviews, 2014-07, Vol.40 (6), p.750-759

2014

Volltextzugriff (PDF)

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

Mayo Clinic proceedings, 2008-05, Vol.83 (5), p.584-594

2008

Volltextzugriff (PDF)

Biomarker Discovery and Validation: Statistical Considerations

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.537-545

2021

Volltextzugriff (PDF)

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2015-10, Vol.10 (10), p.1396-1403

2015

Volltextzugriff (PDF)

1 – 25 von 626

Menü

Weitere Dienste

Einstellungen

KRAS: From undruggable to a druggable Cancer Target

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

The clinical development of MEK inhibitors

Lung Cancer Worldwide

Current Diagnosis and Management of Small-Cell Lung Cancer

MET: a promising anticancer therapeutic target

The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

A systematic review of the business case for corporate social responsibility and firm performance

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

FGFR Signaling as a Target for Lung Cancer Therapy

Tackling the High Cost of Oncology Drugs

All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC

Lung cancer and metastasis: new opportunities and challenges

Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer

A Call to Arms: Reducing Disparities in Lung Cancer Care Worldwide

Controversies in Thoracic Oncology

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

Expanding the KRASG12C Inhibitor Class: What Do We Need Next?

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

Biomarker Discovery and Validation: Statistical Considerations

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Suchergebnisse filtern